China NMPA Drug Inspection - Sichuan Pharmaceutical Co., Ltd. - Amomum villosum

The Guizhou Provincial Food and Drug Administration (NMPA) issued Announcement No. 1, 2018, on May 28, 2018, outlining the results of province-wide drug quality sampling inspections. These inspections, conducted across drug production, distribution enterprises, and medical institutions, aimed to bolster drug quality oversight and protect public health. The regulatory findings identified 24 batches of drugs from numerous manufacturers that did not comply with established quality standards. Companies such as Chengdu Yicheng Pharmaceutical Co., Ltd., Yunnan Suimin Biotechnology Development Co., Ltd., Hunan Nanguo Yaodu Traditional Chinese Medicine Processed Slices Co., Ltd., and Guizhou Shunjian Pharmaceutical Co., Ltd., were among those with non-compliant products. Main violations included discrepancies in 'Inspection (Total Ash),' 'Inspection (Moisture),' 'Properties,' 'Appearance,' 'Content determination,' and 'Visible Foreign Matter.' The regulatory framework primarily cited was the *Chinese Pharmacopoeia* (various editions), alongside a specific State Food and Drug Administration Standard for one product. Following these findings, regulatory departments are actively investigating the non-compliant drugs and related entities, pursuing legal actions, and have implemented timely control measures to ensure public safety.